Texas Yale Capital Corp. Savara Inc Transaction History

Texas Yale Capital Corp.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 24, 2019	SELL	$2.37 - $11.7 $73,797 - $364,314	-31,138 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$6.71 - $8.6 $104,467 - $133,893	15,569 Added 100.0%	31,138 $230,000
Q2 2018 Aug 07, 2018	SELL	$8.55 - $13.76 $85,500 - $137,600	-10,000 Reduced 39.11%	15,569 $176,000
Q1 2018 May 03, 2018	SELL	$8.99 - $14.95 $30,152 - $50,142	-3,354 Reduced 11.6%	25,569 $235,000
Q4 2017 Feb 07, 2018	BUY	$8.26 - $16.76 $238,903 - $484,749	28,923	28,923 $429,000

141

158M

55.6K

600

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $331M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Texas Yale Capital Corp., based on Form 13F filings with the SEC.

Stay updated on Texas Yale Capital Corp. with notifications on news.